Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chemotherapy].

Keisuke Aiba1

  • 1Dept. of Internal Medicine, Clinical Oncology Program, Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 3, 2004
PubMed
Summary

Chemotherapy for colorectal cancer has advanced significantly. FOLFOX 4 is now a standard treatment, offering improved survival and acceptable toxicity compared to other regimens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.

International journal of clinical oncology·2020
Same author

A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.

The oncologist·2020
Same author

S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial.

Clinical colorectal cancer·2020
Same author

Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan.

In vivo (Athens, Greece)·2019
Same author

Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy.

Anticancer research·2018
Same author

[Retrospective Investigation of the Risk Factors for Severity in Panitumumab-Induced Hypomagnesemia].

Gan to kagaku ryoho. Cancer & chemotherapy·2018

Area of Science:

  • Medical Oncology
  • Gastrointestinal Oncology
  • Cancer Chemotherapy

Background:

  • 5-fluorouracil (5-FU) has been a cornerstone in colorectal cancer treatment.
  • Biochemical modulation with leucovorin (FL) improved response rates (20-30%) and median survival (10-12 months).
  • Combination regimens like IFL and de Gramont regimen showed improved efficacy but varying toxicity profiles.

Purpose of the Study:

  • To review the evolution of colorectal cancer chemotherapy.
  • To highlight the efficacy and safety of FOLFOX 4 as a standard treatment.
  • To discuss emerging therapies including molecular target agents.

Main Methods:

  • Review of established and novel chemotherapy regimens for colorectal cancer.
  • Analysis of clinical trial data on response rates, median survival, and toxicity.
  • Comparison of FOLFOX 4 with other regimens like IFL and IROX.

Main Results:

  • FOLFOX 4 demonstrated improved median survival and acceptable toxicity, establishing it as a standard for advanced colorectal cancer.
  • The combination of IFL and bevacizumab showed a median survival of 20 months.
  • FOLFOX 4 was found to be more active and less toxic than IFL and IROX in a phase III study.

Conclusions:

  • FOLFOX 4 represents a significant advancement in colorectal cancer chemotherapy.
  • Molecular target agents, such as bevacizumab, hold promise for further improving patient outcomes.
  • Future research will focus on integrating molecular targeted therapies into treatment strategies.

Related Experiment Videos